Abstract

Equine infectious anemia virus (EIAV) is a lentivirus similar to HIV that infects horses. Clinical and experimental studies demonstrating immune control of EIAV infection hold promise for efforts to produce an HIV vaccine. Antibody infusions have been shown to block both wild-type and mutant virus infection, but the mutant sometimes escapes. Using these data, we develop a mathematical model that describes the interactions between antibodies and both wild-type and mutant virus populations, in the context of continual virus mutation. The aim of this work is to determine whether repeated vaccinations through antibody infusions can reduce both the wild-type and mutant strains of the virus below one viral particle, and if so, to examine the vaccination period and number of infusions that ensure eradication. The antibody infusions are modelled using impulsive differential equations, a technique that offers insight into repeated vaccination by approximating the time-to-peak by an instantaneous change. We use impulsive theory to determine the maximal vaccination intervals that would be required to reduce the wild-type and mutant virus levels below one particle per horse. We show that seven boosts of the antibody vaccine are sufficient to eradicate both the wild-type and the mutant strains. In the case of a mutant virus infection that is given infusions of antibodies targeting wild-type virus (i.e., simulation of a heterologous infection), seven infusions were likewise sufficient to eradicate infection, based upon the data set. However, if the period between infusions was sufficiently increased, both the wild-type and mutant virus would eventually persist in the form of a periodic orbit. These results suggest a route forward to design antibody-based vaccine strategies to control viruses subject to mutant escape.

Highlights

  • Equine infectious anemia virus (EIAV) is a lentivirus that primarily infects horses and shares many characteristics with HIV, including its viral structure, genome, life cycle and transmission via blood

  • EIAV infection is a substantial concern for equine health worldwide—one of only 11 infections of equids requiring reporting to the OIE, the World Organization for Animal

  • We investigated the case of control of heterologous infection by neutralizing antibodies (NAbs) by setting W (0) = 0 and M(0) > 0

Read more

Summary

Introduction

Equine infectious anemia virus (EIAV) is a lentivirus that primarily infects horses and shares many characteristics with HIV, including its viral structure, genome, life cycle and transmission via blood. EIAV establishes a persistent infection and is transmitted between hosts by biting flies [1]; the virus is prevalent in warmer climates, not exclusively so [2]. EIAV infection is a substantial concern for equine health worldwide—one of only 11 infections of equids requiring reporting to the OIE, the World Organization for Animal. EIAV infection has a global distribution, and recent reports have documented. Diverse strains have been found; far, phylogenetics has identified six clades globally, though the extent of EIAV diversity is expected to be higher in actuality [6]. There is no treatment for animals infected with EIAV

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call